H.C. Wainwright analyst Robert Burns lowered the firm’s price target on Revolution Medicines (RVMD) to $72 from $73 and keeps a Buy rating on the shares following the Q1 report. The firm is factoring in higher operating expenses moving forward.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
- Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on RVMD:
- Promising Developments in Revolution Medicines’ RAS(ON) Pipeline for NSCLC Treatment
- Revolution Medicines’ Earnings Call: Optimism Amid Rising Costs
- Revolution Medicines price target lowered to $80 from $87 at Guggenheim
- Revolution Medicines price target raised to $75 from $70 at Oppenheimer
- Revolution Medicines: Strategic Advancements in NSCLC Treatment Drive Buy Rating